Седация 

Литература

1. Clinical practice guidelines for the management of pain, agitation and delirium in adult patients in intensive care unit. American College of Critical Care Medicine (ACCM) in conjunction with Society of Critical Care Medicine (SCCM) and American Society of Health-System Pharmacists (ASHP). Critical Care, 2019. – Vol.41, №, 1, p. 263 –
2. Ramsey M.A. et al. Controlled sedation with alpahoalone – aplodolone. Brit. Med. J. 1974, v 2 , pp 657- 659
3. Holzman R.S., Kullen D.J., EichhamJ .H., Phillip J.H. Guidilines for sedation for non-anesthesiologists during diagnostic and therapeutic procedures. The Risk management Committee of the department of Anaesthesiaof Harvard Medical School //J. Clin. , 1994. Vol.6(4). P.265 – 276.
4. Козлов И.А. Современные подходы к седации в отделениях реанимации и интенсивной терапии //Медицинский алфавит. Неотложная медицина, 2013, №1, с. 22 – 31.
5. Rotondi AJ, Chelluri L, Sirio C, et al (2002) Patients’ recollections of stressful experiences while receiving prolonged mechanical ventilation in an intensive care unit. Criti Care Med 30:746-752
6. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371: 126–34.
7. Лихванцев В.В. Опасности и осложнения общей анестезии. М., МИА, 2014, 199 с.
8. Steiner L. Postoperative delirium. Eur. J. Anaestesiol. 2011; 28: 628-636.
9. Mackensen G.B., Gelb A.W. Postoperative cognitive deficits: more questions than answers. Eur. J. Anaesthesiol. 2004; 21: 85-88.
10. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000; 342:1471–7.

11. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371: 126–34.
12. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. 2009; 373:1874–82.
13. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a ran- domised trial. Lancet. 2010;375:475–80.
14. Rosenblatt M & Van Ness JW. Estimation of the bispectrum. Annali Mathematical Statistical 1972; 36:1120–1136.
15. Sigl JC & Chamoun NG. An introduction to bispectral analysis for the electroencephalogram. Journal of Clinical Monitoring 1994; 10: 392–404.
16. Bruhn J, Bouillon TW & Shafer SL. Bispectral index (BIS) and burst suppression: revealing a part of the BIS algorithm. Journal of Clinical Monitoring and Computing 2000; 16: 593–596.
17. American Psychiatric Association: American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2006. Arlington, VA, American Psychiatric Association. 2006:72–74.
18. Лихванцев В.В. Неспецифический делирий в ПИТ. Анестезиология и реаниматология, 2015, №2, с 45 – 54.
19. Barr J, Zomorodi K, Bertaccini EJ, et al: A double-blind, randomized comparison of i.v.lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology2001; 95:286–298
20. Shafer A: Complications of sedation with midazolam in the intensive care unit and acomparison with other sedative regimens. Crit Care Med, 1998; 26:947–956.
21. Swart EL, Zuideveld KP, de Jongh J, et al: Population pharmacodynamicmodelling oflorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically illpatients. Eur J ClinPharmacol, 2006; 62:185–194
22. Swart EL, de Jongh J, Zuideveld KP, et al: Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. Am J Kidney Dis2005; 45:360–371.
23. Swart EL, Zuideveld KP, de Jongh J, et al: Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J ClinPharmacol, 2004; 57:135–145
24. McKeage K, Perry CM: Propofol: A review of its use in intensive care sedation of adults. CNS Drugs 2003; 17:235–272
25. Carson SS, Kress JP, Rodgers JE, et al: A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med2006; 34:1326–1332.
26. Barr J, Egan TD, Sandoval NF, et al: Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology2001; 95:324–333
27. Riker RR, Fraser GL: Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy2005; 25(5 Pt2):8S–18S
28. Walder B, Tramèr MR, Seeck M: Seizure-like phenomena and propofol: A systematic review. Neurology2002; 58:1327–1332
29. Iyer VN, Hoel R, Rabinstein AA: Propofol infusion syndrome in patients with refractory status epilepticus: An 11-year clinical experience. Crit Care Med, 2009; 37:3024–3030
30. Parviainen I, Uusaro A, Kälviäinen R, et al: Propofol in the treatment of refractory status epilepticus. Intensive Care Med, 2006; 32:1075–1079
31. Voss LJ, Sleigh JW, Barnard JP, et al: The howling cortex: Seizures and general anesthetic drugs. 2008; 107:1689–1703. Roberts RJ,
32. Barletta JF, Fong JJ, et al: Incidence of propofol-related infusion syndrome in critically ill adults: A prospective, multicenter study. Crit Care2009; 13:R169
33. Kam PC, Cardone D: Propofol infusion syndrome. Anaesthesia, 2007; 62:690–701
34. Ugur F., Gilcu N., Boyaci A. Intrathecal infusion therapy with dexmedetomidine supplemented morphine in cancer pain. Scand., 2007; 51: 388
35. Venn RM, Grounds RM: Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions. Br J Anaesth 2001; 87:684–690
36. Riker RR, Shehabi Y, Bokesch PM, et al; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group: Dexmedetomidine vs midazolam for sedation of critically ill patients: A randomized trial. JAMA 2009; 301:489–499
37. Shehabi Y, Ruettimann U, Adamson H, et al: Dexmedetomidine infusion for more than 24 hours in critically ill patients: Sedative and cardiovascular effects. Intensive Care Med 2004; 30:2188–2196
38. Pandharipande PP, Pun BT, Herr DL, et al: Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: The MENDS randomized controlled trial. JAMA 2007; 298:2644–2653].
39. Hospira Inc: FDA package insert for dexmedetomidine. Available at: http://www.precedex.com/wp-content/uploads/2010/11/Prece- dex_PI.pdf. Accessed October 2010]
40. Riker RR, Shehabi Y, Bokesch PM, et al; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group: Dexmedetomidine vs midazolam for sedation of critically ill patients: A randomized trial. JAMA 2009; 301:489–499
41. Eger EI 2nd, Saidman L.J, Brandstater B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology. 1965; 26 (6): 756–763.
42. Saidman L.J., M.D., Eger E.I. II, M.D., Munson E.S. Minimum alveolar concentrations of methoxyflurane, halothane, ether and cyclopropane in man: correlation with theories of anesthesia. Anesthesiology 1967; 28: 994-1001.
43. Nakajima R., Nakajima Y., Ikeda K. Minimum alveolar concentration of sevoflurane in elderly patients. BJA 1993; 70(3): 273–275.
44. Лихванцев В. В. Практическое руководство по анестезиологии. М.: МИА; 2011, 540 с..
45. Замятин М.Н., Теплых Б.А. Вводная анестезия севофлураном у взрослых (учебно-методические рекомендации). 2007, 26 с.
46. Katoh T., Ikeda K. The minimum alveolar concentration (MAC) of sevoflurane in humans. Anesthesiology 1987; 66: 301-303
47. Katoh T., Bito H., Sato S. Influence of age on hypnotic requirement, bispectral index and 95% SEF associated with sedation induced by sevoflurane. Anesthesiology 2000 Ene; 92 (1): 55–61.
48. Dwyer R., Bennett H.L., Eger E.I. II, Heilbron D. Effects of isoflurane and nitrous oxide in subanesthetic concentrations on memory and responsiveness in volunteers. Anesthesiology 1992; 77: 888–898.
49. Misra S., Koshy T. A review of the practice of sedation with inhalational anaesthetics in the intensive care unit with the AnaConDa device. Indian J. Anaesth. 2012; 56 (6): 518–523.
50. L’her E., Dy L., Pili R., Prat G., et al. Feasibility and potential cost/benefit of routine isoflurane sedation using an anesthetic-conserving device: a prospective observational study. Respir Care. 2008; 53 (10): 1295–1303.
51. Tempia A., Olivei M.C., Calza E., et al. The anesthetic conserving device compared with conventional circle system used under different flow conditions for inhaled anesthesia. Anesth Analg. 2003 Apr;96(4):1056-61, table of contents.
52. Röhm K.D., Wolf M.W., Schöllhorn T., et al. Short term sevoflurane sedation using the anaesthetic conserving device after cardiothoracic surgery. Intensive Care Med. 2008; 34: 1683–1689.
53. Мороз В.В., Лихванцев В.В., Гребенчиков О.А. и соавт. Принципы безопасной работы с ингаляционными анестетиками. Учебно-методическое пособие для врачей. — М., 2011. — 28 с.
54. Berton J., Sargentini C., Nguyen J.L., et al. AnaConDa reflection filter: Bench and patient evaluation of safety and volatile anesthetic conservation. Anesth. Analg. 2007; 104: 130–134.
55. Лихванцев В.В., Мироненко А.В., Габитов М.В., Скрипкин Ю.В., Данилов М.П. Применение устройства AnaConDa в интенсивной терапии. Учебно-методическое пособие для врачей.-М., 2015, 26 c. ISBN 978-5-98511-260-3.

56. Лихванцев В. В., Гребенчиков О.А., Филлиповская Ж.С., Лопатин А.Ф., Черпаков Р.А., Скрипкин Ю.В. Анестетическое кондиционирование: определение, механизмы реализации, клиническая значимость. Вестник интенсивной терапии, 2014, №4, 55 – 59.